Online Program

293812
Prevalence of secondary conditions and co-morbidity in people living with paralysis in the United States


Monday, November 4, 2013 : 11:00 a.m. - 11:15 a.m.

Heidi G. Fredine, MPH, Center for Development & Disability, University of New Mexico, Albuquerque, NM
Jennifer Rowland, PhD MPH, Department of Physical Therapy, Galveston, TX
Douglas Landsman, PhD, Christopher and Dana Reeve Foundation, Short Hills, NJ
People with paralysis are at high risk for developing secondary conditions, such as pressure sores, and comorbid conditions, such as diabetes. However, little is known about the prevalence of these conditions in the population with paralysis in the United States. In this session we will present preliminary data from a national, random-digit dial survey of over 70,000 households conducted in 2012 to estimate the prevalence of secondary and comorbid conditions in people with paralysis. Given that some subsets of people with paralysis may be more prone to secondary and comorbid conditions than others, analysis will be broken out by cause and diagnoses, such as spinal cord injury, arthritis, traumatic brain injury, and others, including combinations of these conditions. The data to be reported come from a national, random-digit dial survey of over 70,000 households initiated in 2012. Comorbidity comparisons will be made between this survey's findings and estimates from general and broader disability populations taken from the national surveys including the Behavioral Risk Factor Surveillance Survey.

Learning Areas:

Epidemiology

Learning Objectives:
Explain the prevalence of secondary conditions and co-morbidities in people with paralysis in the US

Keyword(s): Disability

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I have twenty years of esperience in disability research
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.